SusanaMariaCamposMD

Oncology • Boston, MA

Assistant Professor, Medicine, Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Campos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Campos' full profile

Already have an account?

Office
44 Binney St
# Dana-Far
Boston, MA 02115
Phone+1 617-632-5269

Fax+1 617-632-1930

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1992 - 1995
Georgetown University School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1995 - 2025
NH State Medical License 2023 - 2025

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Valdecoxib in Treating Chronic Pain in Cancer Patients Start of enrollment: 2001 Jan 01
Completed
Not Applicable
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients Start of enrollment: 2005 Sep 01
Completed
Phase 1
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Start of enrollment: 2006 Aug 01
Completed
Phase 2
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Start of enrollment: 2007 Aug 01
Completed
Phase 2
Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function Start of enrollment: 2006 Apr 01
Completed
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma Start of enrollment: 2008 Sep 01
Completed
Phase 2
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies Start of enrollment: 2010 Feb 01
Completed
Phase 1
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 1, Phase 2
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 2
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Tivozanib As Maintenance Therapy In GYN Start of enrollment: 2013 Nov 01
Terminated
Phase 2
Dostarlimab and Cobolimab in Advanced Cervical Cancer Start of enrollment: 2024 Mar 11
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomi...
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, Anna Tavormina, Ursula A Matulonis
Gynecologic Oncology. 2024-09-01
10 citations
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Nadeem R Abu-Rustum, Catheryn M Yashar, Rebecca Arend, Emma Barber, Kristin Bradley
Journal of the National Comprehensive Cancer Network. 2024-03-01
4 citations
Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers.
Rachel A Pozzar, Jaclyn A Wall, Anna Tavormina, Embree Thompson, Andrea C Enzinger
Gynecologic Oncology. 2024-02-01

Other

Treatment of locally advanced, recurrent, or metastatic endometrial cancer
Campos SM, Miller DS
http://www.uptodate.com/contents/treatment-of-locally-advanced-recurrent-or-metastatic-endometrial-c
UpToDate, Wolters Kluwer Health - 2013-02-25

Press Mentions

The Latest Advances in Ovarian Cancer TreatmentNovember 4th, 2020
Virtual Danger: Toronto Lab Recreates the World — and May Revolutionize ResearchApril 23rd, 2019
Brought Together by Ovarian Cancer Diagnosis, Two Survivors Look to Help OthersDecember 3rd, 2018
Join now to see all